Study Results
Results available
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Clinical Phase
PHASE4
Total Enrollment
40 participants
Study Classification
INTERVENTIONAL
Study Start Date
2021-09-22
Study Completion Date
2022-03-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study will identify pediatric patients 3-18 years old who have penicillin allergy label in the electronic medical record. Those who are identified will be stratified into no-risk, low-risk and high-risk category using a screening questionnaire. The following definitions will be followed:
No-risk: Patients who are historically labeled with penicillin allergy in the EMR based on family history alone OR those who have tolerated penicillin after a concerning incident without any reaction OR with penicillin allergy label but deny any history of reaction to any form of penicillin on screening questionnaire
Low-risk: Patients with previous reaction not suggestive of anaphylaxis (defined below) AND not requiring hospitalization for the reaction OR reaction considered non- immunologic (e.g. diarrhea, nausea, yeast vaginitis) OR exposure to penicillin- containing antibiotic after the date of reported reaction with no anaphylaxis and hospitalization AND no serious types of delayed reactions such as Steven- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who had delayed reaction (onset more than 24 hours) of isolated, non-progressive symptoms (such as rash/hives alone) also belong to this group.
High-risk: Patients with penicillin allergy label on EMR with previous reaction suggestive of anaphylaxis (defined below) OR requiring hospitalization/epinephrine administration for the reaction OR reactions considered immunologic (angioedema, joint pains) OR involving serious types of reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who were previously diagnosed with penicillin allergy by an allergist also belong to the high-risk group.
Patients in the no-risk group will be immediately delabeled. Patients in the high-risk group will be referred to allergy/immunology for further work up. The focus of this study is to identify the patients who belong to the low-risk group. This group of patients will be subjected to graded oral amoxicillin challenge testing. Those who will have reactions compatible with allergy will have their allergy status retained in the electronic medical record. Those that will not have reactions or those that will have reactions that are not compatible with allergy will be delabeled in the electronic medical record.
No-risk: Patients who are historically labeled with penicillin allergy in the EMR based on family history alone OR those who have tolerated penicillin after a concerning incident without any reaction OR with penicillin allergy label but deny any history of reaction to any form of penicillin on screening questionnaire
Low-risk: Patients with previous reaction not suggestive of anaphylaxis (defined below) AND not requiring hospitalization for the reaction OR reaction considered non- immunologic (e.g. diarrhea, nausea, yeast vaginitis) OR exposure to penicillin- containing antibiotic after the date of reported reaction with no anaphylaxis and hospitalization AND no serious types of delayed reactions such as Steven- Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who had delayed reaction (onset more than 24 hours) of isolated, non-progressive symptoms (such as rash/hives alone) also belong to this group.
High-risk: Patients with penicillin allergy label on EMR with previous reaction suggestive of anaphylaxis (defined below) OR requiring hospitalization/epinephrine administration for the reaction OR reactions considered immunologic (angioedema, joint pains) OR involving serious types of reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who were previously diagnosed with penicillin allergy by an allergist also belong to the high-risk group.
Patients in the no-risk group will be immediately delabeled. Patients in the high-risk group will be referred to allergy/immunology for further work up. The focus of this study is to identify the patients who belong to the low-risk group. This group of patients will be subjected to graded oral amoxicillin challenge testing. Those who will have reactions compatible with allergy will have their allergy status retained in the electronic medical record. Those that will not have reactions or those that will have reactions that are not compatible with allergy will be delabeled in the electronic medical record.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pilot Study to Assess Safety, Preliminary Efficacy and Pharmacokinetics of S.C. Pegcetacoplan (APL-2) in PNH Subjects.
NCT02588833
Paroxysmal Nocturnal Hemoglobinuria
COMPLETED
PHASE1
A Study of Pegcetacoplan in Pediatric Patients With Paroxysmal Nocturnal Hemoglobinuria (PNH)
NCT04901936
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Paroxysmal Hemoglobinuria
RECRUITING
PHASE2
Oral Immunotherapy (OIT) for Peanut Allergy
NCT00815035
Peanut Hypersensitivity
COMPLETED
PHASE2
Study to Investigate Safety, Efficacy of an Anti-IFNγ mAb in Children With Primary Haemophagocytic Lymphohistiocytosis
NCT01818492
Primary Haemophagocytic Lymphohistiocytosis
COMPLETED
PHASE2/PHASE3
Data and Sample Collection Study to Elucidate the Mechanisms of Eosinophilic Disorders
NCT00267501
Eosinophilic Gastrointestinal Disease Eosinophilic Inflammatory Disease
Food Allergy
RECRUITING
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
A. Specific Aims and Hypotheses
General Objective:
To verify pediatric patients with reported penicillin allergy in electronic medical record (EMR) by performing direct oral amoxicillin challenge testing.
Hypothesis: Pediatric patients with reported penicillin allergy in EMR can be verified by performing direct oral amoxicillin challenge testing.
Specific objectives:
1. To identify no-risk, low-risk and high-risk patients among pediatric patients with reported penicillin allergy in EMR through a questionnaire.
Hypothesis: No-risk, low-risk and high-risk pediatric patients with reported penicillin allergy in EMR can be identified using a questionnaire.
2. To be able to delabel pediatric patients with reported penicillin allergy in EMR who are identified as no-risk.
Hypothesis: No-risk pediatric patients with reported penicillin allergy in EMR can be delabeled using a questionnaire.
3. To be able to delabel identified low-risk pediatric patients with reported penicillin allergy in EMR who are verified not allergic to penicillin by direct oral amoxicillin challenge testing.
Hypothesis: Identified low-risk pediatric patients with reported penicillin allergy in EMR using a questionnaire can be verified using direct oral amoxicillin challenge testing.
4. To be able to provide proper referral guidance to patients identified as high-risk and those who failed oral amoxicillin challenge testing to allergy and immunology for further evaluation and management.
Hypothesis: Proper referral guidance to patients identified as high-risk and those who failed oral penicillin challenge testing to allergy and immunology can be provided for their further evaluation and management.
B. Background and Significance Penicillin remains a reliable class of antibiotics that addresses a majority of infections both in outpatient and inpatient settings.(1,2) It is also one of the cheapest antibiotics to use for empiric therapy for susceptible infections.(3,4) Emerging literature suggests that the number of patients with historical penicillin allergy is an overestimate. A growing number of studies show that only approximately 1-10 % of patients with historical penicillin allergy are truly allergic after verified allergy testing is done.(1-3,5,7,8,10,11,12) Despite this, efforts on antibiotic allergy delabeling remains sparse and penicillin allergy remains to be the most common drug allergy reported.
Few institutions have implemented, much less conceptualized, protocols to determine truly allergic patients who have reported penicillin allergy when diagnosed with infections theoretically susceptible to penicillin.(6) One limitation perhaps is the absence of validated questionnaire that uniformly captures accepted levels of risk especially in the pediatric population.(7) As a result, these patients end up receiving alternative antimicrobial agents that pose a risk for emergence of resistance, development of unnecessary intestinal dysbiosis, and increased economic burden to health care resulting in suboptimal clinical outcome. (1-6) Studies aiming to validate direct oral challenge testing as a means of penicillin allergy delabeling is a fertile avenue for this clinical query to be addressed in a cost-effective and timely manner. (8-13)
Identifying patients with no immunologically-mediated penicillin allergy and delabeling them in the electronic medical record (EMR) accordingly will mitigate the use of second-line antibiotics, aid in minimizing development of antimicrobial resistance, ameliorate unnecessary economic burden, and overall lead to positive impact in clinical outcome and patient care. (1,5,7,8,10,11,12) In the same way, this process will also identify patients with true penicillin allergy creating a point-of-care opportunity to provide them proper guidance on the importance of Allergy/Immunology follow-up for further evaluation and management.
C. Methods
Population of Interest:
Patients 3-18 years old admitted at our institution will be screened for inclusion. We will screen approximately 800 patients and enroll 60 patients in our study (based on the weekly census) over a span of 3 months. HIPAA regulations will be strictly observed in data handling to protect patient privacy.
Screening and consenting of patients:
Signed parental consent and verbal consent from study team will be obtained prior to screening. Patients will be screened using a questionnaire to identify risk status. Patients identified as no-risk (EMR label based purely on family history of penicillin allergy, mislabeled patients) will be immediately delabeled in EMR. High-risk patients (those with reaction consistent with IgE mediated reaction or with history of anaphylaxis) will be excluded. Guidance on further care such as referral to an allergist will be recommended if not yet done. Low-risk patients (those with mild reaction not consistent with IgE mediated reaction, no history of serious delayed reaction or no reaction on subsequent penicillin receipt) will be identified to undergo graded direct oral amoxicillin challenge testing.
Oral Amoxicillin Challenge Testing:
Signed parental consent and patient assent (7 years and older) will be obtained prior to challenge testing. Only low-risk patients with parent/guardian in the room and no receipt of anti-histamine 48 hours prior will be challenged. Only patients who can tolerate enteral amoxicillin will be challenged. Rescue kits (containing diphenhydramine, epinephrine and albuterol) will be ready at bedside prior to challenging. Baseline vital signs will be obtained prior to challenging. Oral challenge testing will be graded: initial 10% of the dose followed by remaining 90% of the dose (total dose 45 mg/kg with maximum of 1000 mg) 30 minutes apart. Vital signs will be repeated 30 minutes after the first dose, 30 minutes after the second dose and finally 60 minutes after the second dose. Study team will administer amoxicillin doses and monitor for signs of amoxicillin allergic reaction. Any reaction during the testing will be assessed by trained study team member. A clinical event note will be written in the EMR for any reaction occurring during the testing as well the management implored to mitigate reaction.
Delabeling:
Low-risk patients who passed the challenge testing will be delabeled in EMR. Documentation of the result will be sent to patient's primary care doctor (with permission from parent) for guidance on future use of penicillin.
General Objective:
To verify pediatric patients with reported penicillin allergy in electronic medical record (EMR) by performing direct oral amoxicillin challenge testing.
Hypothesis: Pediatric patients with reported penicillin allergy in EMR can be verified by performing direct oral amoxicillin challenge testing.
Specific objectives:
1. To identify no-risk, low-risk and high-risk patients among pediatric patients with reported penicillin allergy in EMR through a questionnaire.
Hypothesis: No-risk, low-risk and high-risk pediatric patients with reported penicillin allergy in EMR can be identified using a questionnaire.
2. To be able to delabel pediatric patients with reported penicillin allergy in EMR who are identified as no-risk.
Hypothesis: No-risk pediatric patients with reported penicillin allergy in EMR can be delabeled using a questionnaire.
3. To be able to delabel identified low-risk pediatric patients with reported penicillin allergy in EMR who are verified not allergic to penicillin by direct oral amoxicillin challenge testing.
Hypothesis: Identified low-risk pediatric patients with reported penicillin allergy in EMR using a questionnaire can be verified using direct oral amoxicillin challenge testing.
4. To be able to provide proper referral guidance to patients identified as high-risk and those who failed oral amoxicillin challenge testing to allergy and immunology for further evaluation and management.
Hypothesis: Proper referral guidance to patients identified as high-risk and those who failed oral penicillin challenge testing to allergy and immunology can be provided for their further evaluation and management.
B. Background and Significance Penicillin remains a reliable class of antibiotics that addresses a majority of infections both in outpatient and inpatient settings.(1,2) It is also one of the cheapest antibiotics to use for empiric therapy for susceptible infections.(3,4) Emerging literature suggests that the number of patients with historical penicillin allergy is an overestimate. A growing number of studies show that only approximately 1-10 % of patients with historical penicillin allergy are truly allergic after verified allergy testing is done.(1-3,5,7,8,10,11,12) Despite this, efforts on antibiotic allergy delabeling remains sparse and penicillin allergy remains to be the most common drug allergy reported.
Few institutions have implemented, much less conceptualized, protocols to determine truly allergic patients who have reported penicillin allergy when diagnosed with infections theoretically susceptible to penicillin.(6) One limitation perhaps is the absence of validated questionnaire that uniformly captures accepted levels of risk especially in the pediatric population.(7) As a result, these patients end up receiving alternative antimicrobial agents that pose a risk for emergence of resistance, development of unnecessary intestinal dysbiosis, and increased economic burden to health care resulting in suboptimal clinical outcome. (1-6) Studies aiming to validate direct oral challenge testing as a means of penicillin allergy delabeling is a fertile avenue for this clinical query to be addressed in a cost-effective and timely manner. (8-13)
Identifying patients with no immunologically-mediated penicillin allergy and delabeling them in the electronic medical record (EMR) accordingly will mitigate the use of second-line antibiotics, aid in minimizing development of antimicrobial resistance, ameliorate unnecessary economic burden, and overall lead to positive impact in clinical outcome and patient care. (1,5,7,8,10,11,12) In the same way, this process will also identify patients with true penicillin allergy creating a point-of-care opportunity to provide them proper guidance on the importance of Allergy/Immunology follow-up for further evaluation and management.
C. Methods
Population of Interest:
Patients 3-18 years old admitted at our institution will be screened for inclusion. We will screen approximately 800 patients and enroll 60 patients in our study (based on the weekly census) over a span of 3 months. HIPAA regulations will be strictly observed in data handling to protect patient privacy.
Screening and consenting of patients:
Signed parental consent and verbal consent from study team will be obtained prior to screening. Patients will be screened using a questionnaire to identify risk status. Patients identified as no-risk (EMR label based purely on family history of penicillin allergy, mislabeled patients) will be immediately delabeled in EMR. High-risk patients (those with reaction consistent with IgE mediated reaction or with history of anaphylaxis) will be excluded. Guidance on further care such as referral to an allergist will be recommended if not yet done. Low-risk patients (those with mild reaction not consistent with IgE mediated reaction, no history of serious delayed reaction or no reaction on subsequent penicillin receipt) will be identified to undergo graded direct oral amoxicillin challenge testing.
Oral Amoxicillin Challenge Testing:
Signed parental consent and patient assent (7 years and older) will be obtained prior to challenge testing. Only low-risk patients with parent/guardian in the room and no receipt of anti-histamine 48 hours prior will be challenged. Only patients who can tolerate enteral amoxicillin will be challenged. Rescue kits (containing diphenhydramine, epinephrine and albuterol) will be ready at bedside prior to challenging. Baseline vital signs will be obtained prior to challenging. Oral challenge testing will be graded: initial 10% of the dose followed by remaining 90% of the dose (total dose 45 mg/kg with maximum of 1000 mg) 30 minutes apart. Vital signs will be repeated 30 minutes after the first dose, 30 minutes after the second dose and finally 60 minutes after the second dose. Study team will administer amoxicillin doses and monitor for signs of amoxicillin allergic reaction. Any reaction during the testing will be assessed by trained study team member. A clinical event note will be written in the EMR for any reaction occurring during the testing as well the management implored to mitigate reaction.
Delabeling:
Low-risk patients who passed the challenge testing will be delabeled in EMR. Documentation of the result will be sent to patient's primary care doctor (with permission from parent) for guidance on future use of penicillin.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Penicillin Allergy
Penicillin Sensitivity
Penicillin Reaction
Penicillin Intolerance
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
NON_RANDOMIZED
Intervention Model
SEQUENTIAL
Patients will be screened by questionnaire to determine No risk, Low risk, or High Risk for penicillin allergic reaction. Those that are deemed Low Risk based on questionnaire, will be subsequently challenged with graded oral amoxicillin challenge.
Primary Study Purpose
OTHER
Blinding Strategy
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low Risk Patients
This is the group of patients who will undergo the graded oral amoxicillin challenge testing. Total dose of the amoxicillin will be 45 mg/kg (maximum of 1000 mg). 10 % of this dose will be given first followed by 90 % of the dose 30 minutes after. Each dose will be given only once.
Group Type
EXPERIMENTAL
Graded Oral Amoxicillin Challenge
Intervention Type
DRUG
Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
De-labelling in electronic medical record
Intervention Type
OTHER
Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
Referral to Allergy Immunology/Retention of Allergy Label
Intervention Type
OTHER
Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
No Risk Patients
Patients in the group will be de-labeled in the electronic medical record for No Risk for allergic reaction to amoxicillin based on screening questionnaire.
Group Type
OTHER
De-labelling in electronic medical record
Intervention Type
OTHER
Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
High Risk
Patients in this group are deemed high risk for allergic reaction to penicillin based on screening questionnaire and will remain labeled with allergy in the electronic medical record. They will be referred as outpatient to allergy-immunology for further evaluation.
Group Type
OTHER
Referral to Allergy Immunology/Retention of Allergy Label
Intervention Type
OTHER
Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Graded Oral Amoxicillin Challenge
Oral amoxicillin at 45 mg/kg (maximum of 1000 mg) to be divided into two doses: 10 % initial dose and then 90% remaining dose - doses will be separated by 30 minute interval
Intervention Type
DRUG
De-labelling in electronic medical record
Patients with No Risk for allergic reaction will be de-labelled for allergy in the electronic medical record.
Intervention Type
OTHER
Referral to Allergy Immunology/Retention of Allergy Label
Patients deemed to be High Risk for allergic reaction will be referred to Allergy Immunology as outpatient and allergy label will be retained.
Intervention Type
OTHER
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Amoxicillin Challenge
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients 3-18 years old admitted at our institution with penicillin allergy label in electronic medical record
* Patients with available parent/s or legal guardian who can give both written and verbal consent to the oral challenge testing
* Patients with available parent/s or legal guardian during the conduct of oral amoxicillin challenge testing
\- Patients who will be identified as low-risk patients based on the standardized screening questionnaire. Low-risk group patients are those patients with previous reaction not suggestive of anaphylaxis AND not requiring hospitalization for the reaction OR reaction considered non-immunologic (e.g. diarrhea, nausea, yeast vaginitis) OR exposure to penicillin-containing antibiotic after the date of reported reaction with no anaphylaxis and hospitalization AND no serious types of delayed reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. - ---- Patients who had delayed reaction (onset more than 24 hours) of isolated, non-progressive symptoms (such as rash/hives alone) also belong to this group.
* Patients with available parent/s or legal guardian who can give both written and verbal consent to the oral challenge testing
* Patients with available parent/s or legal guardian during the conduct of oral amoxicillin challenge testing
\- Patients who will be identified as low-risk patients based on the standardized screening questionnaire. Low-risk group patients are those patients with previous reaction not suggestive of anaphylaxis AND not requiring hospitalization for the reaction OR reaction considered non-immunologic (e.g. diarrhea, nausea, yeast vaginitis) OR exposure to penicillin-containing antibiotic after the date of reported reaction with no anaphylaxis and hospitalization AND no serious types of delayed reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. - ---- Patients who had delayed reaction (onset more than 24 hours) of isolated, non-progressive symptoms (such as rash/hives alone) also belong to this group.
Exclusion Criteria
* Patients who cannot tolerate amoxicillin/penicillin by enteral route.
* Patients with no parents or legal guardian available to give both written and verbal consent to the oral challenge testing
* Patients with no available parents or legal guardian during the conduct of oral amoxicillin challenge testing
* Patients currently on antihistamine or have received antihistamine in the previous 48 hours
* Patients who are critically ill
* Patients who have been vomiting more than twice in the past 24 hours or are actively vomiting
* Patients with respiratory symptoms warranting oxygen therapy or pulmonary finding of wheezing or stridor
* Patients identified as having anaphylactic reaction to penicillin in the electronic medical record
* Patients who will be identified as no-risk patients based on the standardized screening questionnaire. No-risk group patients are those patients who are historically labeled with penicillin allergy in the EMR based on family history alone OR those who have tolerated penicillin after a concerning incident without any reaction OR with penicillin allergy label but deny any history of reaction to any form of penicillin on screening questionnaire
* Patients who will be identified as high-risk patients based on the standardized screening questionnaire. High-risk group patients are those patients with penicillin allergy label on EMR with previous reaction suggestive of anaphylaxis OR requiring hospitalization/epinephrine administration for the reaction OR reactions considered immunologic (angioedema, joint pains) OR involving serious types of reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who were previously diagnosed with penicillin allergy by an allergist also belong to the high-risk group.
* Patients with no parents or legal guardian available to give both written and verbal consent to the oral challenge testing
* Patients with no available parents or legal guardian during the conduct of oral amoxicillin challenge testing
* Patients currently on antihistamine or have received antihistamine in the previous 48 hours
* Patients who are critically ill
* Patients who have been vomiting more than twice in the past 24 hours or are actively vomiting
* Patients with respiratory symptoms warranting oxygen therapy or pulmonary finding of wheezing or stridor
* Patients identified as having anaphylactic reaction to penicillin in the electronic medical record
* Patients who will be identified as no-risk patients based on the standardized screening questionnaire. No-risk group patients are those patients who are historically labeled with penicillin allergy in the EMR based on family history alone OR those who have tolerated penicillin after a concerning incident without any reaction OR with penicillin allergy label but deny any history of reaction to any form of penicillin on screening questionnaire
* Patients who will be identified as high-risk patients based on the standardized screening questionnaire. High-risk group patients are those patients with penicillin allergy label on EMR with previous reaction suggestive of anaphylaxis OR requiring hospitalization/epinephrine administration for the reaction OR reactions considered immunologic (angioedema, joint pains) OR involving serious types of reactions such as Steven-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), acute interstitial nephritis (AIN), drug-induced hepatitis or other documented organ injury, drug rash eosinophilia systemic symptoms (DRESS), hemolytic anemia, drug-induced cytopenia, and serum sickness. Patients who were previously diagnosed with penicillin allergy by an allergist also belong to the high-risk group.
Minimum Eligible Age
3 Years
Maximum Eligible Age
18 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Hospitals Cleveland Medical Center
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Ankita Desai
Associate Professor, Director of Pediatric Antimicrobial Stewardship
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Ankita Desai, MD
Role: PRINCIPAL_INVESTIGATOR
University Hospitals Cleveland Medical Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hospitals Rainbow Babies and Children's Hospital
Cleveland, Ohio, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Vyles D, Adams J, Chiu A, Simpson P, Nimmer M, Brousseau DC. Allergy Testing in Children With Low-Risk Penicillin Allergy Symptoms. Pediatrics. 2017 Aug;140(2):e20170471. doi: 10.1542/peds.2017-0471. Epub 2017 Jul 3.
Reference Type
RESULT
du Plessis T, Walls G, Jordan A, Holland DJ. Implementation of a pharmacist-led penicillin allergy de-labelling service in a public hospital. J Antimicrob Chemother. 2019 May 1;74(5):1438-1446. doi: 10.1093/jac/dky575.
Reference Type
RESULT
Blumenthal KG, Ryan EE, Li Y, Lee H, Kuhlen JL, Shenoy ES. The Impact of a Reported Penicillin Allergy on Surgical Site Infection Risk. Clin Infect Dis. 2018 Jan 18;66(3):329-336. doi: 10.1093/cid/cix794.
Reference Type
RESULT
Au LYC, Siu AM, Yamamoto LG. Cost and Risk Analysis of Lifelong Penicillin Allergy. Clin Pediatr (Phila). 2019 Oct;58(11-12):1309-1314. doi: 10.1177/0009922819853014. Epub 2019 Jun 19.
Reference Type
RESULT
Sagar PS, Katelaris CH. Utility of penicillin allergy testing in patients presenting with a history of penicillin allergy. Asia Pac Allergy. 2013 Apr;3(2):115-9. doi: 10.5415/apallergy.2013.3.2.115. Epub 2013 Apr 26.
Reference Type
RESULT
Arnold A, Sommerfield A, Ramgolam A, Rueter K, Muthusamy S, Noble V, von Ungern-Sternberg BS, Lucas M. The role of skin testing and extended antibiotic courses in assessment of children with penicillin allergy: An Australian experience. J Paediatr Child Health. 2019 Apr;55(4):428-432. doi: 10.1111/jpc.14220. Epub 2018 Sep 13.
Reference Type
RESULT
Shenoy ES, Macy E, Rowe T, Blumenthal KG. Evaluation and Management of Penicillin Allergy: A Review. JAMA. 2019 Jan 15;321(2):188-199. doi: 10.1001/jama.2018.19283.
Reference Type
RESULT
Kuruvilla M, Shih J, Patel K, Scanlon N. Direct oral amoxicillin challenge without preliminary skin testing in adult patients with allergy and at low risk with reported penicillin allergy. Allergy Asthma Proc. 2019 Jan 1;40(1):57-61. doi: 10.2500/aap.2019.40.4184.
Reference Type
RESULT
Graham F, Tsabouri S, Caubet JC. Hypersensitivity reactions to beta-lactams in children. Curr Opin Allergy Clin Immunol. 2018 Aug;18(4):284-290. doi: 10.1097/ACI.0000000000000453.
Reference Type
RESULT
Mustafa SS, Conn K, Ramsey A. Comparing Direct Challenge to Penicillin Skin Testing for the Outpatient Evaluation of Penicillin Allergy: A Randomized Controlled Trial. J Allergy Clin Immunol Pract. 2019 Sep-Oct;7(7):2163-2170. doi: 10.1016/j.jaip.2019.05.037. Epub 2019 Jun 4.
Reference Type
RESULT
Moral L, Caubet JC. Oral challenge without skin tests in children with non-severe beta-lactam hypersensitivity: Time to change the paradigm? Pediatr Allergy Immunol. 2017 Dec;28(8):724-727. doi: 10.1111/pai.12800. Epub 2017 Oct 3.
Reference Type
RESULT
Kelso JM. Provocation Challenges to Evaluate Amoxicillin Allergy in Children. JAMA Pediatr. 2016 Jun 6;170(6):e160282. doi: 10.1001/jamapediatrics.2016.0282. Epub 2016 Jun 6. No abstract available.
Reference Type
RESULT
Mill C, Primeau MN, Medoff E, Lejtenyi C, O'Keefe A, Netchiporouk E, Dery A, Ben-Shoshan M. Assessing the Diagnostic Properties of a Graded Oral Provocation Challenge for the Diagnosis of Immediate and Nonimmediate Reactions to Amoxicillin in Children. JAMA Pediatr. 2016 Jun 6;170(6):e160033. doi: 10.1001/jamapediatrics.2016.0033. Epub 2016 Jun 6.
Reference Type
RESULT
Sampson HA, Munoz-Furlong A, Campbell RL, Adkinson NF Jr, Bock SA, Branum A, Brown SG, Camargo CA Jr, Cydulka R, Galli SJ, Gidudu J, Gruchalla RS, Harlor AD Jr, Hepner DL, Lewis LM, Lieberman PL, Metcalfe DD, O'Connor R, Muraro A, Rudman A, Schmitt C, Scherrer D, Simons FE, Thomas S, Wood JP, Decker WW. Second symposium on the definition and management of anaphylaxis: summary report--Second National Institute of Allergy and Infectious Disease/Food Allergy and Anaphylaxis Network symposium. J Allergy Clin Immunol. 2006 Feb;117(2):391-7. doi: 10.1016/j.jaci.2005.12.1303.
Reference Type
RESULT
Lieberman P, Nicklas RA, Randolph C, Oppenheimer J, Bernstein D, Bernstein J, Ellis A, Golden DB, Greenberger P, Kemp S, Khan D, Ledford D, Lieberman J, Metcalfe D, Nowak-Wegrzyn A, Sicherer S, Wallace D, Blessing-Moore J, Lang D, Portnoy JM, Schuller D, Spector S, Tilles SA. Anaphylaxis--a practice parameter update 2015. Ann Allergy Asthma Immunol. 2015 Nov;115(5):341-84. doi: 10.1016/j.anai.2015.07.019. No abstract available.
Reference Type
RESULT
Bauer ME, MacBrayne C, Stein A, Searns J, Hicks A, Sarin T, Lin T, Duffey H, Rannie M, Wickstrom K, Yang C, Bajaj L, Carel K. A Multidisciplinary Quality Improvement Initiative to Facilitate Penicillin Allergy Delabeling Among Hospitalized Pediatric Patients. Hosp Pediatr. 2021 May;11(5):427-434. doi: 10.1542/hpeds.2020-001636. Epub 2021 Apr 13.
Reference Type
RESULT
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Statistical Analysis Plan
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STUDY20200136
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Phase 2 Safety and Efficacy Study of Zilucoplan (RA101495) to Treat PNH Patients
NCT03078582
COMPLETED
PHASE2
Pinpoint Trial: Prebiotics IN Peanut Oral ImmunoTherapy
NCT05138757
ACTIVE_NOT_RECRUITING
PHASE1/PHASE2
A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Sublingual/Oral Immunotherapy for the Treatment of Peanut Allergy
NCT01084174
COMPLETED
PHASE1/PHASE2
Efficacy and Safety Study of Kedrion IVIG 10% to Treat Subjects With Primary Immunodeficiency (PID)
NCT01581593
COMPLETED
PHASE3
A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN or C3G
NCT06419205
WITHDRAWN
PHASE2
Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis
NCT05067127
COMPLETED
PHASE3
Study in Pediatric Subjects With Peanut Allergy to Evaluate Efficacy and Safety of Dupilumab as Adjunct to AR101 (Peanut Oral Immunotherapy)
NCT03682770
COMPLETED
PHASE2
Oral Immunotherapy for Peanut Allergy (PMIT)
NCT00597675
COMPLETED
PHASE2
Study of Ravulizumab in Pediatric Participants With Primary IgAN
NCT07024563
RECRUITING
PHASE3
A Study to Assess Immune Response in Pediatric Kidney Transplant Recipients Treated With Daclizumab (Zenapax)
NCT02576145
COMPLETED
PHASE4
GOALIE: Intramuscular vs. Enteral Penicillin Prophylaxis to Prevent Progression of Latent RHD Trial
NCT05693545
RECRUITING
PHASE2
Epicutaneous Immunotherapy in Peanut Allergy in Children
NCT01197053
COMPLETED
PHASE2
Study of Immune Globulin Intravenous (Human) GC5107 in Subjects With Primary Humoral Immunodeficiency
NCT02783482
COMPLETED
PHASE3
Peanut Reactivity Reduced by Oral Tolerance in an Anti-IgE Clinical Trial
NCT01781637
COMPLETED
PHASE1/PHASE2
Evaluating the Safety and Efficacy of Oral Encapsulated Microbiota Transplantation Therapy in Peanut Allergic Patients
NCT05695261
RECRUITING
PHASE2
Evaluating Peanut Immunotherapy Dissolving Film in Healthy Subjects
NCT03070561
COMPLETED
EARLY_PHASE1
Omalizumab With Oral Food Immunotherapy With Food Allergies Open Label Safety Study in a Single Center
NCT01510626
COMPLETED
PHASE1
A Phase IIa Study to Assess the Safety, Efficacy, and Pharmacokinetics of Subcutaneously Administered Pegcetacoplan (APL-2) in Subjects With PNH
NCT03593200
COMPLETED
PHASE2
Oral Peanut Immunotherapy
NCT01324401
COMPLETED
NA
Hybrid Immunotherapy for Hemophagocytic LymphoHistiocytosis
NCT01104025
COMPLETED
PHASE2
A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial
NCT00580606
COMPLETED
PHASE1/PHASE2
Clinical Study Using Biologics to Improve Multi OIT Outcomes (COMBINE)
NCT03679676
COMPLETED
PHASE2
Multi Immunotherapy to Test Tolerance and Xolair
NCT02626611
COMPLETED
PHASE2
A Study of Xolair in Peanut-Allergic Subjects Previously Enrolled in Study Q2788g
NCT00382148
COMPLETED
PHASE2
Peanut Oral Immunotherapy in Children
NCT01867671
COMPLETED
PHASE2